elsamitrucin

Elsamitrucin is a heterocyclic antineoplastic antibiotic isolated from the bacterium Actinomycete strain J907-21. It acts as a cytostatic agent by intercalating into DNA at guanine-cytosine (G-C)-rich sequences and inhibiting topoisomerase I and II, leading to single-strand breaks and inhibition of DNA replication. Elsamitrucin has demonstrated broad-spectrum in vitro cytotoxicity against various tumor cell lines and was evaluated in clinical trials for several cancers, including non-small cell lung cancer, breast cancer, colorectal cancer, ovarian cancer, and non-Hodgkin's lymphoma. While it showed modest activity in relapsed or refractory non-Hodgkin's lymphoma patients, it was not found to be active in other solid tumors during phase II trials[1][2][3][5][6].

Other names

elsamicin Aelsamitrucinaelsamitrucine